Format

Send to

Choose Destination
Leuk Res. 2012 Jul;36(7):803. doi: 10.1016/j.leukres.2012.03.016. Epub 2012 Apr 12.

Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia.

Author information

1
Department of Clinical and Molecular Bio-Medicine, Section of Hematology, Oncology and Clinical Pathology, University of Catania, Italy. fsematol@tiscali.it
PMID:
22502918
DOI:
10.1016/j.leukres.2012.03.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center